Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $33.45M
• Dividend Yield: N/A
• Average Volume (3M): 88.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 64
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.94
• Shares Outstanding: 22,300,043
• 10 Day Avg. Volume: 53,606
• 30 Day Avg. Volume: 88,778
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.00
• Price Target Upside: 900.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Boundless Bio Inc.'s overall stock score is primarily impacted by its financial struggles as a biotechnology start-up with no revenue and high operational costs. Improvements in equity provide some stability, but the company remains reliant on external funding. Technical indicators show weak performance, with the stock trending downward and nearing oversold conditions. The negative P/E ratio further highlights valuation challenges.

Positive Factors

Financial Stability

BOLD reports cash and cash equivalents of $167.1 mn, which provides a cash runway into 4Q26, ensuring financial stability for continued operations and research.

Innovative Research

BOLD authored a Nature publication demonstrating the rationale for CHK1 inhibition as an ecDNA-targeted therapy, highlighting their innovative approach in cancer treatment.

Pipeline Development

The third ecDNA therapy program targeting kinesin is progressing through lead optimization, showing continued development in their pipeline.

Negative Factors

Drug Discontinuation

BOLD announced discontinuation of BBI-825 (RNR inhibitor) after the Part 1 portion of the Ph 1/2 STARMAP trial demonstrated a lack of dose-proportional exposure in the pharmacokinetic data.

Leadership Changes

The company announced leadership changes, including a CMO transition and the departure of the CBO.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio Inc. (BOLD) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in targeting extrachromosomal DNA (ecDNA) in cancer cells, aiming to address genomic amplification and improve treatment outcomes. Boundless Bio operates within the biopharmaceutical sector, leveraging cutting-edge research to create products that can potentially transform cancer care.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Boundless Bio Inc. is experiencing typical start-up issues in the biotechnology sector with no revenue and high operational costs, leading to continued losses. While there are some improvements in equity and liquidity, the company heavily relies on external financing.

Income Statement

Boundless Bio Inc. has consistently reported zero revenue over the past years, indicating no sales or commercialized products. The net income has been negative, showing persistent losses, with net losses increasing year-over-year. The negative EBIT and EBITDA margins further highlight operational challenges and high costs relative to non-existent revenues.

Balance Sheet

The company has shown improvement in its equity position, moving from negative equity to a positive equity situation, which indicates better financial stability. However, the debt-to-equity ratio improvement is due to increasing equity rather than reducing liabilities. The company's cash and short-term investments have increased, providing liquidity, but liabilities remain substantial.

Cash Flow

Operating cash flow remains negative, reflecting the company's inability to generate cash from its core operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. However, significant financing activities suggest reliance on external funding to sustain operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-775.00K	0.00	-957.00K	-942.00K	-682.00K	0.00
	EBIT
-68.78M	-73.27M	-54.80M	-46.47M	-25.30M	-134.37M
	EBITDA
-67.75M	-73.27M	-48.48M	-45.53M	-24.62M	-121.36M
	Net Income Common Stockholders
-61.06M	-65.36M	-49.43M	-45.90M	-25.21M	-128.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
104.88M	152.11M	120.75M	66.72M	73.03M	414.31M
	Total Assets
142.06M	206.41M	129.89M	76.83M	113.72M	472.56M
	Total Debt
2.75M	47.63M	2.19M	5.18M	377.00K	7.07M
	Net Debt
-33.61M	21.05M	-21.51M	-5.77M	-33.91M	-137.28M
	Total Liabilities
22.69M	55.77M	256.98M	158.53M	151.91M	29.80M
	Stockholders Equity
119.37M	150.64M	-127.08M	-81.70M	-38.19M	442.75M
Cash Flow		Free Cash Flow
-59.30M	-63.38M	-47.49M	-40.66M	-25.28M	-119.59M
	Operating Cash Flow
-56.96M	-60.84M	-46.85M	-39.60M	-23.25M	-107.98M
	Investing Cash Flow
-12.11M	-26.10M	-38.26M	16.13M	-59.28M	-185.05M
	Financing Cash Flow
88.33M	89.82M	97.90M	126.00K	105.53M	398.46M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.64, below the 50-day MA of 2.00, and below the 200-day MA of 3.08, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 23.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$4.11B	-18.71	-17.06%	5.82%	26.02%	-79.79%
CRSP	46 Neutral	$3.17B	―	-19.20%	―	-89.95%	-123.71%
BEAM	45 Neutral	$2.22B	―	-43.94%	―	-83.18%	-144.95%
NTLA	41 Neutral	$835.39M	―	-54.00%	―	59.55%	3.09%
EDIT	39 Underperform	$103.72M	―	-98.10%	―	-58.64%	-40.05%
VERV	39 Underperform	$463.51M	―	-36.36%	―	174.98%	25.06%
BOLD	31 Underperform	$33.45M	―	-554.86%	―	―	―

Boundless Bio Inc. Corporate Events

Boundless Bio Shifts Focus and Restructures Leadership Team

Boundless Bio announced significant updates to its ecDNA-directed therapy programs and leadership team. The company has decided not to advance its BBI-825 program due to complex treatment landscapes and is focusing resources on BBI-355, with initial clinical data expected in 2025, and the third ecDTx program, aiming for a development candidate by mid-2025. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo stepping in as interim CMO. These strategic decisions extend the company’s operational funding into 2027, demonstrating a commitment to advancing its therapeutic pipeline and addressing unmet oncogene-amplified cancer needs.